Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 5, 2014, Pages 1079-1087

  Hasegawa, Junichi ^a,b   Nishimura, Junichi ^a,b   Mizushima, Tsunekazu ^a   Miyake, Yasuhiro ^a,c,d   Kim, Ho Min ^a,b   Takemoto, Hiroyoshi ^a,e,f   Tamagawa, Hroshi ^a,g,h   Noura, Shingo ^a,i   Fujii, Makoto ^a,j   Fujie, Yujiro ^a,k,l   Kato, Takeshi ^a,c,m   Miwa, Hideaki ^b   Takemasa, Ichiro ^a   Ikeda, Masataka ^a,n   Yamamoto, Hirofumi ^a   Sekimoto, Mistugu ^a,n   Nezu, Riichiro ^a,b,d   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c Minoh City Hospital   (Japan)

^d Nishinomiya Municipal Central Hospital   (Japan)

^e Sakai City Medical Center   (Japan)

^f Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^g OSAKA GENERAL MEDICAL CENTER   (Japan)

^h OTEMAE HOSPITAL   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^k Saiseikai Senri Hospital   (Japan)

^l OSAKA POLICE HOSPITAL   (Japan)

^m KANSAI ROSAI HOSPITAL   (Japan)

ⁿ OSAKA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

Bevacizumab; Capecitabine; Neoadjuvant chemotherapy; Oxaliplatin; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; OXALIPLATIN;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; LYMPH NODE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PELVIC INFLAMMATORY DISEASE; PERIPHERAL NEUROPATHY; PILOT STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CANCER; SURGICAL INFECTION; THERAPY DELAY; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS;

EID: 84900806017     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2417-9     Document Type: Article

References (30)

1. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum (2012) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17:1-29
2. Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479-1482 (Pubitemid 16095660)
3. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van Houwelingen HC, van de Velde CJ (1999) Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1,411 patients. Eur J Surg Oncol 25:368-374 (Pubitemid 29364222)
4. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M (2000) Preoperative radiotherapy for respectable rectal cancer: a meta-analysis. JAMA 284:1008-1015 (Pubitemid 30659131)
5. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646
6. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
7. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. N Engl J Med 355:1114-1123 (Pubitemid 44394918)
8. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620-4625 (Pubitemid 46630960)
9. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: nSABP R-03. J Clin Oncol 27:5124-5130
10. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336:980-987
11. Holm T, Singnomklao T, Rutqvist LE, Cedermark B (1996) Adjuvant preoperative radiotherapy in patients with rectal carcinoma: adverse effects during long term follow-up of two randomized trials. Cancer 78:968-976 (Pubitemid 26284860)
12. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer. Increased bowel dysfunction in irradiated patients: a dutch colorectal cancer group study. J Clin Oncol 23:6199-6206
13. Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, Rutten HJ, Wiggers T, Kranenbarg EK, Leer JW, Stiggelbout AM (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847-1858 (Pubitemid 46211362)
14. Japanese Society for Cancer of the Colon and Rectum (2013) Case treated in 2005. Survival analysis. Multi-institutional registry of large bowel cancer in Japan 31:144-153
15. Schrag D, Weiser MR, Goodman KA, Gonen M, Cercek A, Reidy DL, Temple LK, Wong WD, Paty P, Saltz L (2010) Neoadjuvant FOLFOX-bev without radiation for locally advanced rectal cancer. J Clin Oncol 28:3511
16. Fernandez-Martos C, Estevan R, Salud A, Pericay C, Gallen M, Sierra E, Serra J, Pera M, Maurel J, Delgado S, Safont MJ, Roig JV, Aparicio J, Feliu J, Garcia D, Vera R, Suarez J, Alonso V, Martin-Richard M, Brown G (2012) Neoadjuvant capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. J Clin Oncol 30:3586
17. Sobin LH, Gospodarowicz MK, Wittekind C (2009) International Union Against Cancer (UICC) TNM Classification of Malignant Tumours, 7th edn. Oxford, Wiley-Blackwell, UK
18. Patel UB, Brown G, Rutten H, West N, Sebag-Montefiore D, Glynne-Jones R, Rullier E, Peeters M, Van Cutsem E, Ricci S, Van de Velde C, Kjell P, Quirke P (2012) Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol 19:2842-2852
19. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, Minsky BD, Wong WD (2005) Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241:829-838 (Pubitemid 40604929)
20. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985-992
21. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD) (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016 (Pubitemid 351392040)
22. Leichman L (2006) Neoadjuvant chemotherapy for disseminated colorectal cancer: changing the paradigm. J Clin Oncol 24:3817-3818
23. .Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855 (Pubitemid 46223989)
24. Chong G, Cunningham D (2005) Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 23:9063-9066
25. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases Treatment Group (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European colorectal metastases treatment group. Eur J Cancer 43:2037-2045 Epub 2007 Sep 4
26. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012
27. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
28. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn L, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147 (Pubitemid 38524883)
29. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835. doi:10.1200/JCO.2007.13.7679
30. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES (2013) Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational breast cancer research consortium trial 017. Cancer 119:1776-1783